Efficacy and safety of inhaled formoterol 4.5 and 9 μg twice daily in Japanese and European COPD patients: Phase III study results

BMC Pulmonary Medicine

Volumn 11, Issue , 2011, Pages

  Bogdan, Miron A ^a   Aizawa, Hisamichi ^b   Fukuchi, Yoshinosuke ^c   Mishima, Michiaki ^d   Nishimura, Masaharu ^e   Ichinose, Masakazu ^f  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b KURUME UNIVERSITY   (Japan)

^c JUNTENDO UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY   (Japan)

^e HOKKAIDO UNIVERSITY   (Japan)

^f WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FORMOTEROL; PLACEBO; SALBUTAMOL; BRONCHODILATING AGENT; ETHANOLAMINE DERIVATIVE;

ADULT; AGED; ARTICLE; BACKACHE; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED CLINICAL TRIAL; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG FATALITY; FEMALE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; OUTCOME VARIABLE; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EUROPE; FORCED EXPIRATORY VOLUME; JAPAN; MIDDLE AGED; MULTICENTER STUDY; SPIROMETRY; TREATMENT OUTCOME;

ADULT; AGED; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; ETHANOLAMINES; EUROPE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; JAPAN; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPIROMETRY; TREATMENT OUTCOME;

EID: 81055127637     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-11-51     Document Type: Article

References (21)

1. Chamberlain AM, Schabath MB, Folson AR. Associations of chronic obstructive pulmonary disease with all-cause mortality in Blacks and Whites: the atherosclerosis risk in communities (ARIC) study. Ethn Dis 2009, 19:308-314. 2826210, 19769014.
2. Ekberg-Aronsson M, Pehrsson K, Nilsson JA, Nilsson PM, Löfdahl CG. Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis. Respir Res 2005, 6:98. 10.1186/1465-9921-6-98, 1224873, 16120227.
3. Lung Health Study Research Group Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000, 343:1902-1999. Lung Health Study Research Group.
4. Pauwels RA, Löfdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999, 340:1948-1953. 10.1056/NEJM199906243402503, 10379018.
5. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003, 22:912-919. Erratum in: Eur Respir J 2004, 24:1075, 10.1183/09031936.03.00027003, 14680078.
6. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C, . TRial of Inhaled STeroids ANd long-acting beta2 agonists study group Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease:a randomised controlled trial. Lancet 2003, 361:449-456. Erratum in: Lancet 2003, 361:1660, 10.1016/S0140-6736(03)12459-2, 12583942, TRial of Inhaled STeroids ANd long-acting beta2 agonists study group.
7. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003, 21:74-81. Erratum in: Eur Respir J 2003, 21:912, 10.1183/09031936.03.00031402, 12570112.
8. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, . TORCH investigators Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775-789. 10.1056/NEJMoa063070, 17314337, TORCH investigators.
9. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (updated 2010). Global Initiative for Chronic Obstructive Lung Disease (GOLD)., http://www.goldcopd.org/
10. Salpeter SR, Buckley NS, Salpeter EE. Meta-analysis: anticholinergics, but not β-agonists, reduce severe exacerbations and respiratory mortality. Int J COPD 2006, 21:1011-1019.
11. Rodrigo GJ, Nannini LJ, Rodriguez-Roisin R. Safety of long-acting β-agonists in stable COPD: a systematic review. Chest 2008, 133:1079-1087. 10.1378/chest.07-1167, 18460518.
12. Campbell M, Eliraz A, Johansson G, Tornling G, Nihlén U, Bengtsson T, Rabe K. Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease. Respir Med 2005, 99:1511-1520. 10.1016/j.rmed.2005.08.016, 16199148.
13. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 2002, 19:398-404. 10.1183/09031936.02.00063702, 11936514.
14. Nelson HS, Weiss ST, Bleecker ET, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial. Chest 2006, 129:15-26. 10.1378/chest.129.1.15, 16424409.
15. Benhamou D, Cuvelier A, Muir JF, Leclerc V, Le Gros V, Kottakis J, Bourdeix I. Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). Respir Med 2001, 95:817-821. 10.1053/rmed.2001.1161, 11601748.
16. Bouros D, Kottakis J, Le Gros V, Overend T, Della Cioppa G, Siafakas N. Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV(1) reversibility. Curr Med Res Opin 2004, 20:581-586. 10.1185/030079904125003368, 15140323.
17. Dahl R, Greefhorst LA, Nowak D, Nonikov V, Byrne AM, Thomson MH, Till D, Della Cioppa G, . Formoterol in Chronic Obstructive Pulmonary Disease I Study Group Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164:778-784. Formoterol in Chronic Obstructive Pulmonary Disease I Study Group.
18. Di Marco F, Verga M, Santus P, Morelli N, Cazzola M, Centanni S. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation on chronic obstructive pulmonary disease: a pilot study. Respir Med 2006, 100:1925-1932. 10.1016/j.rmed.2006.03.007, 16626956.
19. Maesen BL, Westermann CJ, Duurkens VA, van den Bosch JM. Effects of formoterol in apparently poorly reversible chronic obstructive pulmonary disease. Eur Respir J 1999, 13:1103-1108. 10.1034/j.1399-3003.1999.13e27.x, 10414411.
20. Rossi A, Kristufek P, Levine BE, Thomson MH, Till D, Kottakis J, Della Cioppa G, . Formoterol in Chronic Obstructive Pulmonary Disease (FICOPD) II Study Group Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002, 121:1058-1069. 10.1378/chest.121.4.1058, 11948033, Formoterol in Chronic Obstructive Pulmonary Disease (FICOPD) II Study Group.
21. Kottakis J, Cioppa GD, Creemers J, Greefhorst L, Lecler V, Pistelli R, Overend T, Till D, Rapatz G, Le Gros V, Bouros D, Siafakas N. Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study. Can Respir J 2002, 9:107-115.